Status:
UNKNOWN
Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
Lead Sponsor:
Seoul National University Hospital
Conditions:
Normal Tension Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.
Detailed Description
* Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of glaucoma type) * Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by suppression of aqueo...
Eligibility Criteria
Inclusion
- over 18 years old
- baseline IOP under 22 mmHg,both anterior chamber angle \> Grade 3\~4 by Shaffer grading system
Exclusion
- IOP over 22 mmHg by Goldmann applanation tonometer
- other types of glaucoma except open angle
- other IOP lowering treatment
- chronic or recurrent Hx. of ocular inflammation
- using contact lens
- any other ocular disease that could affect visual field examination (diabetic retinopathy, macular disease, uveitis, scleritis, optic neuritis, anterior ischemic optic neuropathy)
- intraocular or glaucoma surgery within 6 months
- Hx. of allergic reaction to timolol or brimonidine
- bronchial asthma
- moderate to severe chronic obstructive pulmonary disease
- heart failure
- 2\~3 degree A-V block,
- MAO inhibitor use
- anti depressant use
- untreated pheochromocytoma
- pregnant
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01446497
Start Date
October 1 2010
End Date
August 1 2012
Last Update
October 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744